‘First of its kind’ medication can significantly reduce heart attacks and strokes
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
Daily4d
Newly Diagnosed Diabetes Elevates Risk of Coronary Artery Disease: Study
A recent study from Taiwan revealed a concerning link between newly detected diabetes mellitus and a higher prevalence of ...
EurekAlert!1d
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
The #1 Habit for Better Heart Health If You Have Diabetes, According to Experts
Discover how regular exercise can strengthen your heart, regulate blood sugar and lower heart disease risk for those with ...
Hosted on MSN13h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Diabetes and other chronic conditions are becoming common. Here's how public health efforts can help bring rates down.
Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
News Medical5d
What's Next for Semaglutide? Beyond Diabetes and Weight Loss
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Rolling Out6d
Kidney disease speeds up heart risks, study finds
Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.
News Medical on MSN14h
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...